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Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate
origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer
have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest
that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose
that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian
compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of
these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian
origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin
advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.
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Adenocarcinoma of Mullerian origin was first described by
Dr. Swerdlow in 1959 [1]. The original manuscript entitled,
“Mesothelioma of the pelvic peritoneum resembling
papillary cystadenocarcinoma of the ovary,” described
a patient with a malignant left-sided pelvic mass. The
mass surrounded the left fallopian tube without mucosal
involvement; bilateral ovaries and the right tube were
negative for disease. Histologically, the tumor closely
resembled a papillary ovarian cystadenocarcinoma.
Dr. Swerdlow theorized that while ovarian or tubal
carcinoma was unlikely, the tumor probably developed
from tissue with a similar embryological origin as the
ovary (specifically, the pelvic peritoneum, fallopian tubes,
or uterus). He ultimately concluded that the cancer arose
from the pelvic peritoneum [1]. In retrospect, this case
represents the earliest documentation of adenocarcinoma
of Mullerian origin. There is a growing body of evidence
that suggests this terminology applies to epithelial ovarian,* Correspondence: lauren.cobb@duke.edu
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creativecommons.org/publicdomain/zero/1.0/peritoneal, and tubal cancers, as well as select cancers
previously designated as “cancers of unknown primary”
(CUP). Select endometrial cancers may also be included in
future classifications, but as the treatment paradigms are
different, we chose not to include them in this review.
Recent data regarding the genetics and histopathology
of epithelial ovarian cancer (EOC) has improved our
understanding of ovarian carcinogenesis. These results
and current hypotheses indicate that epithelial ovarian,
peritoneal, and tubal cancers are not distinct entities but
represent a spectrum of disease that originates in the
Mullerian compartment. Due to this new information,
the FIGO staging classification for ovarian, tubal, and
peritoneal cancers was revised (Table 1) [2]. Tubal and
peritoneal cancers are now included in the ovarian cancer
staging classification, and the primary site designated
when possible [2,3]. This new staging exemplifies our
current understanding of the relationship between these
disease entities and challenges our previous classification
of ovarian, peritoneal, and tubal cancers. We and others
assert that this group of gynecologic cancers should be
collectively designated as adenocarcinomas of Mullerian
origin. In this review, we will focus on the incidence,icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Ovarian cancer staging (FIGO 2013 vs. FIGO 1988)
FIGO (1988) FIGO (2013)
I: Tumor limited to the ovaries I: Tumor confined to ovaries or fallopian tube(s)a
IA: Tumor limited to 1 ovary (capsule intact), no tumor on ovarian
surface, no malignant cells in ascites or peritoneal washings
IA: Tumor limited to 1 ovary (capsule intact) or fallopian tube; no tumor
on ovarian or fallopian tube surface; no malignant cells in the ascites
or peritoneal washings
IB: Tumor limited to both ovaries (capsules intact), no tumor on ovarian
surface, no malignant cells in ascites or peritoneal washings
IB: Tumor limited to both ovaries (capsules intact) or fallopian tubes;
no tumor on ovarian or fallopian tube surface; no malignant cells in the
ascites or peritoneal washings
IC: Tumor limited to 1 or both ovaries with any of the following:
capsule ruptured, tumor on ovarian surface, malignant cells in ascites
or peritoneal washings
IC: Tumor limited to 1 or both ovaries or fallopian tube(s) with any of the
following:
IC1: Surgical spill intraoperatively
IC2: Capsule ruptured before surgery or tumor on ovarian or fallopian tube
surface
IC3: Malignant cells in the ascites or peritoneal washings
II: Tumor involves 1 or both ovaries with pelvic extension II: Tumor involves 1 or both ovaries or fallopian tubes with pelvic extension
(below pelvic brim) or primary peritoneal cancerb
IIA: Extension and/or implants on uterus and/or tube(s); no malignant
cells in ascites or peritoneal washings
IIA: Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
IIB: Extension to other pelvic tissues; no malignant cells in ascites or
peritoneal washings
IIB: Extension to other pelvic intra-peritoneal tissues
IIC: Pelvic extension (IIA or IIB) with malignant cells in ascites or
peritoneal washings
III: Tumor involves 1 or both ovaries with microscopically confirmed
peritoneal metastases outside the pelvis and/or regional lymph node
metastasis
III: Tumor involves 1 or both ovaries or fallopian tubes, or primary
peritoneal cancer, with cytologically or histologically confirmed spread
to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal
lymph nodes
IIIA: Microscopic peritoneal metastasis beyond pelvis IIIA1: Positive retroperitoneal lymph nodes only (cytologically or
histologically proven)
IIIA1(i): Metastasis up to 10 mm in greatest dimension
IIIA1(ii): Metastasis more than 10 mm in greatest dimension
IIIA2: Microscopic extra-pelvic (above the pelvic brim) peritoneal involvement
with or without positive retroperitoneal lymph nodes
IIIB: Macroscopic peritoneal metastasis beyond pelvis, 2 cm or less in
greatest dimension
IIIB: Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in
greatest dimension, with or without metastasis to the retro-peritoneal
lymph nodes (includes extension of tumor to capsule of liver and spleen
without parenchymal involvement of either organ)
IIIC: Peritoneal metastasis beyond pelvis more than 2 cm in greatest
dimension and/or regional lymph node metastasis
IIIC: Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm
in greatest dimension, with or without metastasis to the retro-peritoneal
lymph nodes (includes extension of tumor to capsule of liver and spleen
without parenchymal involvement of either organ)
IV: Distant metastasis (excludes peritoneal metastasis) IV: Distant metastasis excluding peritoneal metastases
IVA: Pleural effusion with positive cytology
IVB: Parenchymal metastases and metastases to extra-abdominal organs
(including inguinal lymph nodes and lymph nodes outside of the
abdominal cavity)c
aIt is not possible to have stage I peritoneal cancer.
bDense adhesions with histologically proven tumor cells justify upgrading apparent stage I tumors to stage II.
cExtra-abdominal metastases include transmural bowel infiltration and umbilical deposits.
Adapted from Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Archives of gynecology
and obstetrics. Aug 1 2014.
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We will also review the molecular and pathologic profiling
that support the concept of adenocarcinomas of Mullerian
origin as a unified entity and will assist in diagnostic and
treatment paradigms.Review
Incidence
It is difficult to discern how many annual deaths occur
due to adenocarcinomas of Mullerian origin. While EOC
caused approximately 14,030 deaths in the United States
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it is unclear exactly how many deaths were caused
by peritoneal and tubal cancers. Peritoneal and tubal
carcinomas have been considered rare malignancies
and separate entities from ovarian carcinomas; thus,
epidemiologic studies have proven difficult [6]. Tubal
carcinomas account for only 0.14-1.8% of gynecologic
malignancies [7,8]. In the United States, from 1995–2004,
the age adjusted incidence rates for tubal and peritoneal
carcinomas were 3.7 and 6.8 per million, respectively [6].
Newer theories indicate that the number of peritoneal and
tubal cancers may be grossly underestimated.
Additionally, CUP accounts for 3-5% of malignant
epithelial cancers [9] and in 2012, there were an esti-
mated 31,000 new cases of CUP in the United States
[10]. Potentially 5% of CUP may originate in the female
reproductive system based on data from post mortem
autopsy studies [9,11]. It is important to recognize the
adenocarcinoma of Mullerian origin subset of CUP when
it occurs, because these cancers will typically have a more
favorable prognosis and sensitivity to platinum-based
chemotherapeutic regimens [12]. Identification of adeno-
carcinoma of Mullerian origin, specifically in patients
with CUP, will guide appropriate treatment options,
and provide information regarding prognosis [9,12].
Current classification
Epithelial ovarian cancer classification
EOC classification has changed significantly over the
past decade. The most recent proposed division of EOC
includes two distinct histologic groups: type I and type
II cancers. It should be noted that the type I and type II
classification is generally used to broadly classify ovarian
neoplasms for research purposes based on their unique
clinical and molecular genetic features [13]. The classifi-
cation was not meant to be used for clinical purposes.
Type I tumors include low-grade serous and low-grade
endometrioid cancers, as well as mucinous, clear cell,
and transitional cell carcinomas. Tumors in this category
typically develop from atypical proliferative borderline
tumors, benign cystic lesions, or endometriosis. Transitional
cell tumors and mucinous tumors do not typically have
Mullerian features, but may develop from cortical inclusion
cysts and Walthard cell nests [14]. However, there is
an uncommon subtype of mucinous tumors which
does demonstrate Mullerian (endocervical) characteristics
[15,16]. Generally, type I tumors are more indolent, present
at an earlier stage, are confined to the ovary, and are
often large. When type I tumors, specifically clear cell and
mucinous cancers, are not detected early, they usually
have a worse prognosis than type II cancers [14].
Type II cancers account for approximately 75% of
EOC and the vast majority of ovarian cancer deaths. These
include high-grade serous and high-grade endometrioidcarcinomas, as well as carcinosarcomas and undifferenti-
ated carcinomas. These cancers are typically aggressive and
diagnosed at a later stage [13,14,17]. Until recently the
origin or precursor lesion for the type II cancers was
unknown [18]. However, it is now recognized that the
precursor lesion exists in the fallopian tube, as discussed
later in this review [14,17,19-21].
Fallopian tube cancer classification
As mentioned above, per the 2014 FIGO staging classifi-
cation, tubal and peritoneal cancers are now considered
collectively with ovarian cancer [2]. Regarding histologic
classification, serous tubal carcinomas are most frequent
(49.5-83.3%), followed by endometrioid (8.3%-50%),
mixed (3.9-16.7%), transitional (11.7%), undifferentiated
(7.8-11.3%), mucinous (3%-7.6%), and clear cell (1.9%)
cancers [7]. These histologic subtypes are similar to the
proportions seen in EOC; however, clear cell histology
is more common in EOC, while transitional cell and
undifferentiated histology is more frequent in tubal cancers
[7,8]. In the past, the diagnosis of tubal carcinoma was
made based on pathologic criteria with at least one
the following: 1) the primary tumor arises from the
endosalpinx in the fallopian tube 2) the histologic
pattern resembles epithelial mucosa and is often papillary
in nature 3) there is a clear transition between benign
and malignant epithelium if the wall is involved, and
4) there is no evidence of malignancy in the ovaries
or endometrium, or if tumor is present, there is less tumor
than is present in the fallopian tube [7].
Peritoneal cancer classification
Peritoneal carcinomas have been called multiple names
including peritoneal papillary serous carcinoma, peritoneal
mesothelioma, primary peritoneal carcinoma, and normal-
sized ovary carcinoma syndrome. In 1993, the Gynecologic
Oncology Group established specific guidelines for the
diagnosis of peritoneal carcinoma: 1) ovaries are of normal
size or enlarged only as a result of a benign process 2)
extraovarian involvement is greater than surface ovarian
involvement 3) ovarian involvement does not show
evidence of cortical invasion, is confined to the ovarian
surface epithelium and cortical stroma and is less than
5×5 mm, and 4) histologically, the cancer is primarily of
serous type, appearing similar or identical to ovarian
serous adenocarcinoma of any grade [22]. Historically,
peritoneal cancers have been reported to be more fre-
quently multifocal with diffuse micronodular spread and
more difficult to cytoreduce compared to EOC [23]. In
1994, Fowler et al. characterized the natural history of peri-
toneal adenocarcinoma of Mullerian origin. He reported
that most were classified as serous histology and had either
omental disease or diffuse carcinomatosis [12]. Currently,
while viewed as separate entities, patients with peritoneal
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treated similarly to ovarian cancer with cytoreductive
surgery and platinum-based chemotherapy [24], and now
considered collectively with ovarian and tubal cancer in
the staging guidelines [2].
Theories regarding adenocarcinoma of Mullerian origin
Comprehension of the embryologic origin of the Mullerian
system is critical to understanding the theories surrounding
the origin of ovarian, peritoneal, and tubal cancers. Ovarian
surface epithelium (OSE) is derived from the coelomic
epithelium in early development. The coelomic epithelium
is derived from the mesoderm, consists of the epithelial
lining of the intraembryonic body cavity or coelom, and
overlies the intraembryonic body cavity (which will become
the peritoneum), including the area that will develop into
the gonadal structures. During fetal development,
near the area that will form the gonadal structures,
the coelomic epithelium invaginates to give rise to
the Mullerian (paramesonephric) ducts (which will
ultimately differentiate to become the fallopian tubes,
uterus, cervix, and upper vagina). Therefore, while the
reproductive organs and peritoneum originate from
distinct pathways, the Mullerian epithelia, OSE, and
peritoneal (coelomic) epithelium have a close developmen-
tal relationship (Figure 1) [25].
Ovarian carcinogenesis was previously thought to occur
through the invagination of the OSE into the underlying
stroma to form inclusion cysts. Metaplasia of the epithelium
on the wall of these cysts was proposed to transform
the OSE into the aforementioned cell types and their
corresponding tumors: serous, mucinous, clear cell, endo-
metrioid and transitional cell carcinomas. This theoryFigure 1 Transverse section through the urogenital ridge. Progressing from
intraembryonic cavity and fuse in the midline forming the Mullerian structure
from Swadler, T.W. Langman’s Medical Embryology, 10th Edition. Philadelphia:seems unlikely for two reasons: (1) the normal ovary does
not bear resemblance to the morphologic phenotype of
any of these tumors, and (2) it suggests that ovarian
cancers develop de novo. However, cancers typically
develop in a stepwise fashion from a benign lesion to
a malignancy [14]. An alternate theory proposed that
ovarian tumors develop from nearby paraovarian and
paratubal cysts consisting of Mullerian-type epithelium,
called the “secondary Mullerian system.” As the tumors
grow from these cysts, they infringe upon the ovary,
compress it, and eventually obliterate it, making it appear
as though it is ovarian in origin [14,26]. This theory seems
unlikely as well, given that paratubal and paraovarian cysts
rarely contain precursor lesions resembling serous,
clear cell, or endometrioid carcinomas [14]. However,
the secondary Mullerian system may also include
endosalpingiosis, endometriosis, and endocerviocosis.
Metaplasia from these tissues are commonly observed
in ovarian malignancies [27]; thus, this theory may
account for the development of some ovarian cancers
[27]. The most recent theory proposes that the majority of
serous, endometrioid, and clear cell “primary ovarian”
cancers actually develop from the fallopian tube and
endometrium, the “primary Mullerian system” and will be
discussed further in this review [14,27].
Origin of type I EOC
In type I EOC, there is considerable evidence that clear
cell and endometrioid carcinomas may originate from
endometriosis. The pathogenesis of endometriosis is
complex and theories include retrograde menstruation as
well as metaplasia of extrauterine cells. Retrograde
menstruation would indicate that endometrioid andA to C, the paramesonephric ducts approach each other through the
s (broad ligament of the uterus, fallopian tubes and uterus). *Adapted
Lippincott Williams & Wilkins; 2006: 246.
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primary Mullerian system, which secondarily involves the
ovary [14]. Several studies have demonstrated an increased
risk of ovarian cancer in the setting of endometriosis
[28-30]. A meta-analysis of endometriosis in EOC
concluded that the prevalence of endometriosis was sig-
nificantly higher in women with clear cell cancers (35.9%)
and endometrioid carcinomas (19%), compared to those
with serous (4.5%), and mucinous (1.4%) cancers [31].
The origin of mucinous carcinoma is unclear. It is
commonly accepted that a majority of mucinous cancers
involving the reproductive tract are actually metastases
from extraovarian sites, usually gastrointestinal in origin.
True primary ovarian mucinous carcinomas are uncom-
mon, accounting for only 3% of ovarian carcinomas,
although one recent theory includes mucinous metaplasia
of Brenner (transitional cell) tumors [32]. Brenner tumors
and mucinous carcinomas (intestinal type) may share
similar histogenesis at the tubal peritoneal junction from
transitional cell nests that exist there [13]. As mentioned
previously, an uncommon subtype of mucinous tumors
does demonstrate Mullerian (endocervical) characteristics
[15,16]. Most advanced mucinous cancers are likely
metastatic gastrointestinal and pancreaticobilliary cancers
that involve the ovary and peritoneum.
With regard to low-grade serous carcinoma (LGSC),
multiple studies support the step-wise progression of serous
cystadenoma or adenofibroma to atypical proliferative
serous tumor (atypical serous borderline tumor), to
noninvasive micropapillary serous borderline tumor, toType I: low-grade serous carcinoma
Dualistic pathways in developin
Figure 2 The dualistic pathways in developing low-grade and high-grade
presumed fallopian tube epithelial stem cells that disseminated into the ov
cysts may continue to grow into serous cystadenomas and clonally develo
of low-grade serous carcinomas. In contrast to the step-wise tumor progressio
many high-grade serous carcinomas arise as a result of dissemination of their
fallopian tube fimbriated ends.invasive LGSC (Figure 2) [33]. Previously, we reported
identical hallmark KRAS mutations in serous borderline
ovarian tumors and their associated Mullerian inclusion
cysts, suggesting a relationship between the two. It is
unclear if Mullerian inclusion cysts represent a precursor
lesion, signify metastatic disease from the primary border-
line tumor, or develop due to a metaplastic field effect [34].
While KRAS and BRAF mutations are common in border-
line tumors, NRAS mutations are only seen in carcinomas
and may represent the requisite oncogenic switch to inva-
sive serous cancer [35]. There is also evidence to support
the development of LGSC from fallopian tube precursors
or papillary tubal hyperplasia [14,27,36,37].
Origin of type II EOC
An observation by Piek et al. would eventually revolutionize
hypotheses regarding the origin of high-grade serous
carcinoma (HGSC). In 2001, Piek and colleagues examined
specimens from women who had undergone a risk
reducing bilateral salpingo-oophorectomy who were either
BRCA mutation carriers or had a strong family history of
ovarian cancer. Fifty percent of the specimens had
preinvasive dysplastic lesions (later coined “serous tubal
intraepithelial carcinoma” (STIC)) that resembled HGSC.
Almost all specimens had high levels of p53 protein
accumulation (indicating accumulation of a nonfunctional
p53 protein due to a TP53 genetic mutation). Initially this
new information was interpreted to mean that tubal
carcinoma should be included in the in the spectrum
of BRCA-associated disease [38]. In 2003, Piek et al.TypeII: high-grade serous carcinoma 
g ovarian serous carcinomas
“ovarian” serous carcinoma. The Type I pathway develops from the
ulation site where those stem cells form surface inclusion cysts. Those
p into serous borderline tumors, which represent the precursor lesions
n pathway as observed in Type I serous tumors, in the Type 2 pathway,
precursor lesions, serous tubal intraepithelial carcinomas (STICs), in the
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the fallopian tube epithelium are the precursor lesions for
hereditary and BRCA-mutated ovarian cancer [19].
Further studies performed in BRCA mutation carriers
revealed that benign areas of the tubal epithelium
overexpressing p53 nonfunctional protein may represent a
precursor to STIC in the pathway to the development of
HGSC [21,39]. STICs are present in the majority of serous
ovarian (59-67%), peritoneal (67%), and tubal (100%)
carcinomas [17,21,25]. In contrast, STICs were not
identified in mucinous, endometrioid, or carcinosarcoma
histologic subtypes [40]. In addition, further studies have
reported identical TP53 mutations in paired STIC and the
concurrent HGSC indicating a clonal relationship between
them [20]. While most HGSCs arise from STICs, alterna-
tive pathways in developing HGSC also exist. For instance,
a small number of HGSCs appear to arise from serous
borderline tumors or LGSCs (Figure 3) [27,41].
While it is not clear how STIC is related to the develop-
ment of peritoneal cancers, some have hypothesized that
sloughed tubal cancer cells disseminate into the peritoneal
cavity and implant accordingly. While Sood et al. proposed
hematogenous spread of ovarian cancer cells with a predi-
lection for implantation in the omentum [42], perhaps
both modes of metastasis (peritoneal and hematogenous
dissemination) play a role in Mullerian carcinogenesis.
Overall, contemporary data indicate that endometrioid
and clear cell cancers arise from endometrial tissue with
the fallopian tube as a conduit between the uterus, ovary,A B
C D
Figure 3 A high-grade serous carcinoma arises from a serous borderline tu
carcinoma developing from the papillae (square) in a background of a typi
enlarged and atypical high-grade serous carcinoma cells that organize in a
that high-grade serous carcinoma cells are diffusely positive for p53, a pa
epithelial cells from the background serous borderline tumor are only focallyand peritoneum; serous cancers from STICs in the fallo-
pian tube [36]; Brenner and mucinous cancers from
transitional-type epithelium found at the tubal-peritoneal
junction that secondarily implant or metastasize to the
ovary and peritoneal surfaces; and rare mucinous cancers
from endocervical mucinous neoplasms. Therefore, while
historically documented as separate processes, we would
argue that ovarian, tubal, and peritoneal cancers should be
uniformly referred to as adenocarcinomas of Mullerian
origin given their similar pathogenesis.
Disease outcomes for adenocarcinoma of Mullerian origin
In a recent meta-analysis, Sørensen et al. compared serous
peritoneal, tubal and ovarian cancer with regards to risk
factors, epidemiology, clinicopathology, and molecular
biology to address whether these diseases should be con-
sidered separately. When comparing peritoneal cancers
with ovarian cancers, even though most of these studies
were limited by small sample sizes, nine studies showed
no significant difference in survival [43-51]. Only three
studies showed poorer survival for peritoneal cancers
[52-54]; however, two of these studies had a small
number of patients with peritoneal cancer [52,53].
When comparing tubal cancers to ovarian cancers,
Sørensen et al. sited three studies showing similar
survival between these two disease entities [54-56] and
two showing improved survival for tubal cancers [57,58].
The studies by Usach et al. [57] and Wethington et al. [58]
were large studies using the SEER database and did notmor. A. A low-magnification view shows a focal high-grade serous
cal serous borderline tumor. B. A higher magnification demonstrates
papillary architecture. C and D. Immunohistochemistry of p53 shows
ttern consistent with a missense TP53 mutation while the adjacent
and weakly positive, a pattern consistent with a wild-type TP53 sequence.
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surgery. All of the aforementioned studies had limitations.
Most of these studies included small sample sizes, utilized
differing definitions of optimal cytoreduction, and failed
to include detailed information regarding pathology,
surgery, treatment regimens, recurrences, and confounding
risk factors, making them difficult to compare and then
generalize their findings. Despite an extensive literature
search by Sørensen and colleagues, the small number of
studies as well as their limitations preclude definitive
conclusions regarding survival outcomes between ovarian,
tubal, and peritoneal cancers.
Biomarkers and pathologic assessment for
adenocarcinoma of Mullerian origin
Serum biomarkers are useful for the detection, response
assessment, and prognosis in a variety of solid tumors,
including adenocarcinomas of Mullerian origin. Cancer
antigen 125 (CA125) is the only biomarker commonly
used for monitoring treatment response and cancer
progression in EOC [59], as well as tubal and peritoneal
cancers [60]. CA125 is a glycoprotein encoded by the gene
MUC16. In patients with advanced EOC, CA125 is
elevated (greater than 35 u/mL) approximately 90% of
the time. However, in patients with early stage EOC,
CA125 is elevated only 50-60% of the time. CA125 is
an excellent marker for ovarian cancer, but is nonspecific
and can be abnormal in other benign and malignant indi-
cations. CA125 expression levels also vary by histology
and are elevated in 85% of serous, 65% of endome-
trioid, 40% of clear cell, and 36% of undifferentiated
adenocarcinomas [59].
There are additional markers that are useful to distin-
guish between various solid tumors. These include
carbohydrate antigen 19–9 (CA19-9), carcinoembryonic
antigen (CEA), and human epididymis protein 4 (HE4).
CA19-9 is member of the Lewis blood group antigens
and is elevated in 27% and 76% of serous and mucinous
ovarian cancers, respectively. CEA is a glycoprotein that
is expressed in 25-50% of women with EOC and over
80% of patients with colorectal carcinomas. Human
epididymis protein 4 (HE4) is overexpressed in serous
and endometrioid carcinomas. Unlike CA125, HE4 is
more specific to ovarian malignancy and serum levels are
usually not elevated with nonmalignant processes [59]. A
subset analysis of premenopausal patients enrolled in a
prospective clinical trial (NCT00315692) demonstrated
that HE4 had a sensitivity of 88.9% and a specificity of
91.8% for the detection of malignancy. In this analysis, in-
vasive malignancy was ruled out for 98% of premeno-
pausal women with an elevated CA-125 and a normal
HE4 level [61]. There are other additional markers that
have been used in combination with CA125, including
cancer antigen 15–3 (CA15-3) and tumor associatedglycoprotein 72 (TAG-72). Although CA15-3 is elevated
in 57-71% of ovarian malignancies (versus 2-6% of benign
ovarian processes), it has a low specificity for ovarian
cancer and is primarily used for the diagnosis of breast
malignancies. TAG-72 is expressed more commonly in
gastrointestinal and pancreatic tumors as well as
mucinous ovarian carcinomas [59]. Biomarkers can be
useful for identifying adenocarcinomas of Mullerian
origin in women with CUP, as well as following response
to treatment.
Pathological analysis of adenocarcinoma of Mullerian
origin
Ovarian, tubal, and peritoneal cancers have similar
pathologic findings which vary based on histologic
subtype, but not by primary site of origin. We describe
common histopathologic and immunophenotype findings
for adenocarcinomas of Mullerian origin stratified by the
various subtypes. Pathologic findings support a clear link
between serous ovarian, tubal, and peritoneal cancers.
However, information regarding pathologic similarities
between tubal and peritoneal clear cell, mucinous, and
endometrioid carcinomas is minimal given the relatively
rare frequency of these histologic subtypes.
High-grade serous carcinoma
Histopathology HGSCs of the ovary, fallopian tube, and
peritoneum are almost identical in histopathology.
Microscopically, the architecture could vary from glandu-
lar to complex papillary to solid pattern, with the tumor
cells infiltrating or replacing the surrounding normal
tissues. The papillae are usually large, irregularly branching,
and highly cellular. Psammoma bodies may be present in
varying numbers, but are rarely as numerous as in LGSC.
The marked cytologic atypia and frequent mitotic figures
(including atypical ones) characterize HGSC. The tumor
cells are enlarged, with high nuclear/cytoplasmic ratio and
great variation in size. Tumor giant cells are commonly
seen. The nuclei are of high-grade with vesicular chromatin
and prominent nucleoli [33].
Immunophenotype Immunophenotypically, ovarian and
tubal HGSCs strongly and diffusely express p16, and CK7;
express WT-1, PAX-8, estrogen receptor, CA125 and
E-cadherin in most cases; do not express Her-2, calretinin,
or CK20; and have a high Ki67 proliferative index
(Figure 4) [33,62-65]. The staining pattern for p53 protein
is usually consistent with either a missense mutation
(diffusely and intensely positive) or nonsense/deletion type
mutation (completely negative) [33]. Overall, peritoneal
serous carcinomas almost always demonstrate the
same immunohistochemistry pattern as ovarian and tubal
HGSCs, with minor and inconsistent differences in WT-1,
b-catenin, vimentin and CK20 expression [62,66-69].
A B
C D
Figure 4 Representative microscopic sections of high-grade serous adenocarcinoma of Mullerian origin demonstrating positive immunostaining
for (A) CK-7, (B) WT-1, (C) PAX-8, and (D) negative immunostaining for CK-20.
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Histopathology Similar to HGSC, there is strong evi-
dence to support the tubal origin of LGSC [36]. In general,
LGSC is characterized by micropapillae and small round
nests of neoplastic cells that infiltrate the stroma in a
haphazard pattern, with infrequent mitoses and only mild
variation in tumor cell size and shape of nuclei. The
nuclear/cytoplasmic ratio may be high but the nuclei are
uniform, small, and round to oval. Psammoma bodies are
common and may be numerous. Necrosis or multinucle-
ated tumor giant cells are not features of LGSC. In
contrast to HGSC, LGSC is usually associated with a
non-invasive serous borderline component [33].
Immunophenotype As previously discussed, the precur-
sor lesions for LGSC are presumed to be epithelial inclu-
sion cysts (leading to serous cystadenoma/adenofibroma,
to atypical serous borderline tumor, to noninvasive micro-
papillary serous borderline tumor, to invasive LGSCs).
These epithelial inclusion cysts were previously thought to
arise from invaginations of the OSE that undergo metapla-
sia; however, the inclusion cysts may originate from tubal
epithelia that secondarily implant on disrupted OSE and
invaginate [36]. Li et al. demonstrated that OSE primarily
has a mesothelial phenotype (calretinin(+)/PAX8(−)), while
the majority of epithelial inclusion cysts demonstrate a
tubal phenotype (calretinin(−)/PAX8(+)) [37]. It is not
surprising then that LGSCs also express PAX8. Additionally,
they express ER and WT-1, similar to HGSC. In contrast to
HGSC, LGSC is characterized by decreased expression of
p53 and p16 (usually negative, scattered, or patchy), and a
lower Ki67 proliferative index [33].Low-grade serous peritoneal carcinoma is a rare entity;
and therefore, available information about this disease
is minimal. Schmeler et al. were the first to clinically
describe low-grade serous peritoneal cancer. Patients
were confirmed to have low-grade serous carcinomas
with destructive invasion. Microscopically the cancers
had relatively uniform round to oval nuclei, mild to
moderate atypia, evenly distributed chromatin, and no
more than 12 mitoses per 10 high-power fields (HPF).
Additionally, these patients met the previously described
GOG criteria for peritoneal carcinoma. Specific immuno-
staining was not described [70].Mucinous carcinoma
Histopathology The majority of primary mucinous
tumors of the ovary mimic features of gastric or pancreati-
cobilliary mucinous neoplasms, while another much less
common subtype harbor Mullerian (endocervical) charac-
teristics. A spectrum of morphologic changes from
cystadenoma to atypical proliferative mucinous tumor
(mucinous borderline tumor) to invasive mucinous car-
cinoma can often be appreciated. They are usually large
unilateral neoplasms with a smooth capsule and confined
to the ovary at diagnosis (stage I). Stromal invasion may
be infiltrative or expansile [15,16]. Mucinous tumors of
the fallopian tube and peritoneum are rare, but have been
reported [7,8,24,71].Immunophenotype Ovarian mucinous carcinomas display
predominance of CK7 over CK20. PAX-8 staining is
much less frequent (40%) despite that it is almost universally
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clear cell carcinomas [72]. WT1, ER, PR and p16 are not
expressed in primary mucinous carcinomas. p53 pro-
tein may be present in 30% of cases, but strong and
diffuse overexpression (as found in HGSC) is not
characteristic [33,73-75].
Clear cell carcinoma
Histopathology Clear cell carcinoma has also been asso-
ciated with endometriosis and displays the following archi-
tectural and cytological features: papillary, tubulocystic or
solid architecture; hobnail tumor cells with clear cyto-
plasm; and large, atypical nuclei with conspicuous nucleoli
and only moderate polymorphism. Clear cell carcinoma
papillae are distinguishable from those of serous carcinoma
in that they are short and round, may show eosinophilic
and hyalinized stroma, and are generally lined with only
one or two layers of cells. Hyaline bodies are present in
approximately 25% of cases. Mitoses are less frequent
than in other types of ovarian carcinomas (usually < 5
per 10 HPF) [15,16]. While most literature focuses on
“ovarian” clear cell carcinoma, there are published case
reports of peritoneal and tubal clear cell cancers [76-79].
The histopathologic findings are similar to ovarian clear
cell carcinomas, but immunostaining is not consistently
available [76-78].
Immunophenotype Generally, clear cell carcinomas
display a CK7(+)/CK20(-) phenotype; express PAX-8;
and lack expression of ER and WT-1. p53 and p16
are usually negative, weak, focal or patchy. Hepato-
cyte nuclear factor-1β (HNF-1β) is a specific and sen-
sitive marker for ovarian clear cell carcinomas that is
not expressed in HGSC [80-82].
Endometrioid carcinoma
Histopathology Endometrioid carcinomas of the ovary
highly resemble endometrioid carcinomas of the
uterus in morphology. These cancers may coexist with
endometriosis and arise from endometriotic cysts. They
are mostly low-grade adenocarcinomas demonstrating a
confluent glandular growth pattern with stromal
disappearance, or evidence of stromal invasion and
squamous metaplasia to varied degrees. Fifteen to thirty
percent of patients have concurrent endometrial
hyperplasia or carcinoma [83]. Similar histopathologic
descriptions have been detailed in few case reports
and case series of endometrioid carcinoma of the fallopian
tube, but immunostaining was not described in detail
[76,84-87]. The even rarer entity of endometrioid
carcinoma of the peritoneum has been described in
reference to extraovarian endometriosis-associated malig-
nancy [88-90], however specific immunostaining has not
been described.Immunophenotype Endometrioid carcinomas typically
demonstrate CK7(+)/CK20(-) phenotype; express ER, PR
and PAX-8; but lack WT-1 and p16 expression, as well
as p53 overexpression. Exceptions to these patterns have
been reported in poorly differentiated varieties, which
overlap with HGSC in morphology [33,91].
Molecular determinants of adenocarcinoma of
Mullerian origin
The data regarding the molecular determinants of
adenocarcinoma of Mullerian origin is primarily based
on genomic studies of EOC [92]. However, some studies do
include tubal and peritoneal cancers. Tothill et al. reported
that serous and endometrioid cancers demonstrate a high
degree of molecular heterogeneity and could be categorized
into six subgroups based on gene expression profiling.
Importantly, the primary site of disease could not be used
as a classification parameter [93]. Tothill and colleagues
reported six distinct subtypes referred to as C1-C6. C3
primarily consisted of serous low malignant potential
tumors, while C6 primarily consisted of low-grade, early
stage endometrial cancers. C1, C2, C4, and C5 mainly
contained high-grade serous and high-grade endometrial
cancers. Notably, C5 demonstrated a mesenchymal profile
which was associated with relatively poor overall survival
[93]. This finding is consistent with our understanding of
cells acquiring the mesenchymal phenotype as they
acquire invasiveness in the process of epithelial to
mesenchymal transition (EMT). However, in the TCGA
data set, a correlation between the mesenchymal subtype
and survival was not seen [92]. Further evaluation is needed
to confirm the associations between gene expression
classifications and clinical outcome.
In 2013, Yang and colleagues took an integrated approach
(as opposed to the previous transcriptome approach)
to analyze serous cancers in the TCGA database and
categorize the transcriptional subtypes into integrated
mesenchymal and integrated epithelial subtypes. This
new approach integrated mRNA expression with associated
alterations in genomic, epigenetic, and miRNA systems.
With this approach, Yang et al. were able to uncover a
master miRNA regulatory network that consistently
associated the integrated mesenchymal subtype of serous
cancer with poor overall survival [94].
Additionally, intense interest has focused on using micro-
array data to identify molecularly-defined subgroups of
women with HGSC who may benefit from anti-angiogenic
therapy with bevacizumab. Gourley et al. evaluated a cohort
of HGSC samples from the ICON7 study and identified
three major subgroups; two with upregulation of angiogenic
gene expression and one with upregulation of immune
genes (and concurrent downregulation of angiogenic genes).
Women in the immune subgroup had improved overall
and progression-free survival (PFS) over the other two
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bevacizumab, the immune subgroup had worse PFS
(Hazard ratio (HR) = 1.73 (1.12-2.68)) and overall survival
(HR, 2.00 (1.11-3.61)) compared to those treated with
chemotherapy alone. In contrast, the pro-angiogenic
subgroup treated with bevacizumab had a trend toward
improved PFS [95]. Winterhoff and colleagues examined
another subgroup of the ICON7 trial and reported that
the greatest benefit from bevacizumab appeared in
patients with serous carcinomas with the mesenchymal
subtype (median PFS increased 9.5 months (25.5 [95%CI
21.1, NA] vs. 16 [95%CI 10.5, NA] months, p = 0.053))
[96]. The results from these studies suggest that beva-
cizumab therapy may be directed based on molecular
subtypes. However, further assessment in a phase III
integral biomarker trial is needed to determine if tumor-
derived molecular classifications can direct individualized
treatment with bevacizumab.
These studies all suggest possible new directions for
therapies in serous ovarian cancer and may ultimately
redefine our concept of ovarian cancer subtypes in an
integrated molecular manner. While integral and integrated
molecular biomarkers are critical to our understanding of
cancer and new therapeutic strategies, our discussion
of the molecular determinants of adenocarcinomas
of Mullerian origin will be based on the dualistic
Type I and II ovarian cancer model, recognizing that
this model represents a simplistic categorization. We
will also focus primarily on molecular findings in
epithelial ovarian cancer, as detailed molecular data
for tubal and peritoneal carcinomas is unavailable
(Table 2).Table 2 Subtypes of adenocarcinomas of Mullerian origin
High-grade serous Low-grade serous




Histologic features Positive: p16, CK7, WT-1,
PAX-8, ER, CA125,
E-cadherin












Risk factors Inherited BRCA1/2 mutation
*Origin of Mullerian mucinous tumors is not definitively known.High-grade serous ovarian, tubal, and peritoneal carcinoma
High-grade Mullerian cancers display predominantly
serous histology, but also include some endometrial
carcinomas, carcinosarcomas, and undifferentiated cancers.
While less is known about the molecular profile of
undifferentiated Mullerian tumors and carcinosarcomas, it
appears that gene expression profiles and genetic alterations
are very similar to those found in serous carcinomas
[97,98]. These tumors exhibit a high level of genetic
instability and are characterized by extensive chromosomal
alterations and mutation of the tumor suppressor gene,
TP53 [99,100]. Mutation of TP53 is an early event in the
pathogenesis of HGSC and is found in STICs [20,101].
The presence of TP53 mutations is nearly ubiquitous
(>95%) in HGSC, thus it is not a useful prognostic or
predictive biomarker [100].
The Cancer Genome Atlas (TCGA) Project recently
analyzed mRNA and microRNA expression, exome
sequencing of entire coding regions, copy number
alterations, and methylation of 489 HGSC [92]. The high
degree of genomic instability in these cancers is notable
with 30 regional chromosomal aberrations (8 recurrent
gains and 22 losses), 63 focal areas of amplification,
and 50 focal deletions. By comparison, there were few
mutations in individual genes identified. TP53 was
mutated in nearly all cases (>95%) and the next most
commonly mutated genes were BRCA1 and BRCA2
(germline mutations present in 9% and 8% respectively,
with somatic mutations in an additional 3% of cases).
BRCA inactivation leads to defective repair of double
stranded DNA breaks by homologous recombination.
















ER, PR and p16
Negative: CK20, ER,




p16, CK 20, p53
KRAS mutation PTEN loss PTEN loss
HER2 amplification PIK3CA mutation PIK3CA mutation
ARID1A mutation ARID1A mutation
Endometriosis Endometriosis
Lynch syndrome
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defects in homologous recombination genes, such as
EMSY, PTEN, RAD51C, ATM/ATR, and Fanconi anemia
genes, are present in 50% of all HGSC [92]. This may
indicate that a large proportion of HGSC may be sen-
sitive to treatments targeting DNA repair, such as PARP1
inhibitors.
Significant alterations have also been identified in the
PI3K-AKT pathway. However, unlike type I cancers
(such as clear cell or low-grade endometrioid cancers,
which exhibit mutations in PTEN and PIK3CA), the
pathway alterations in HGSCs are characterized by
deletions (PTEN) and amplifications (PIK3CA, KRAS,
and AKT1/2). Mutations in each individual gene account
for <1% of the alterations. Similarly the retinoblastoma
(Rb) signaling pathway is altered in 67% of cases with
frequent down-regulation of CDKN2A (30%), deletion
of RB1 (8%), and amplification of CCNE1 (20%), with
few mutations found in these genes [92,102]. These data
further support the finding that HGSC are characterized
by generalized genomic instability rather than point
mutations of driver genes.
Molecular signatures have been identified that are
prognostic and/or predictive of response to therapy
[103,104]. Whether or how these molecular signatures
could guide clinical care is unclear. Confirmation of the
initial results as well as biomarker-directed therapeutic
trials are needed to determine if molecular signatures
can be used to guide therapy in women with HGSC.
Low-grade serous carcinoma
Unlike HGSC, LGSCs do not exhibit chromosomal
instability and are not associated with TP53 or BRCA
mutations [105,106]. Instead, mutations in the MAP
kinase pathway are common with mutations in BRAF
(38%) and KRAS (19%) the most frequent [107-109] as
well as NRAS mutations [35]. These mutations also
appear to be mutually exclusive [35,107]. In addition to
the MAPK pathway mutations, LGSCs are more likely to
exhibit increased expression of ER/PR, E-cadherin, PAX2,
and IGF-1 compared to HGSC [110]. LGSC typically
responds poorly to cytotoxic chemotherapy with an
average response rate of only 4% in women with recurrent
disease [111]. Based on studies suggesting that mutations
in MAPK pathway genes act as driver mutations,
inhibitors of the MAPK pathway, and in particular MEK
inhibitors, are of great interest. Indeed, this has led to the
trial of MAPK inhibitors for the treatment of women with
recurrent LGSC. In a phase II trial of selumetinib, a
MEK1/2 inhibitor, 15% of patients had an objective
response to therapy and 65% had stable disease [112].
Further trials are ongoing, but these results present
the potential of targeted individualized therapy based
on a molecular understanding of the disease.Mucinous carcinoma
Unlike HGSCs, in which TP53 and BRCA mutations are
most common, these mutations are relatively rare in
mucinous tumors. Instead, the majority of mucinous
tumors exhibit either HER2 amplification or KRAS
mutation [113]. The KRAS gene encodes the K-Ras protein,
a key member of the RAS/RAF/MEK/ERK/MAP kinase
signaling pathway that transduces various growth signals
from the cell surface to the nucleus. KRAS mutations
resulting in constitutive activation of the G protein are
commonly found in codons 12, 13, and 61 and have been
identified in a number of solid tumors [114]. KRAS
mutations have been described in up to 68% of cases
of mucinous ovarian cancer, while present in only 5%
of non-mucinous tumors [113,115,116]. The large
majority of mutations were identified in codon 12 (94%)
[117]. KRAS mutations are thought to occur early in the
development of these cancers as they are found in
benign, low malignant potential, and borderline tumors of
mucinous histology [117,118]. The high level of KRAS
mutations in mucinous ovarian cancer may have treat-
ment implications as targeted agents are being developed
to target KRAS mutated tumors.
Overexpression/amplification of HER2 (ERBB2), a mem-
ber of the epidermal growth factor receptor family that
acts upstream of KRAS, has been identified in up to 35%
of mucinous ovarian cancer cases [113,119-121]. Ethnic
differences may exist as HER2 positivity was higher in
Asian cohorts [119-121]. While no association was identi-
fied between HER2 status and outcomes, responses of
HER2 amplified mucinous ovarian tumors to HER2 directed
therapy have been reported [120-123].
Clear cell carcinoma
Similar to the other type I Mullerian carcinomas, clear
cell carcinomas are not associated with chromosomal
instability or mutations in TP53 or BRCA. Notably, clear
cell carcinomas of Mullerian origin exhibit distinctive
gene expression profiles from other Mullerian histologies,
while sharing significant expression patterns with clear
cell tumors of the kidney and endometrium [124,125].
Ovarian clear cell carcinomas show increased activa-
tion of angiogenic, hypoxic cell growth, and glucose
metabolic pathways and demonstrate increased sensi-
tivity to anti-angiogenic therapies [126]. Clinical trials
using anti-angiogenic tyrosine kinase inhibitors are
currently in progress.
Nearly 50% of clear cell ovarian carcinomas were
found to harbor ARID1A mutations resulting in loss of
its encoded protein, BAF250a, a subunit of the SWI-SNF
chromatin remodeling complex [127]. Loss of BAF250a
expression is thought to be an early event in the patho-
genesis of clear cell tumors as endometriotic cyst epithe-
lium in direct contact with the tumor also exhibited loss
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did not [128]. Studies have shown that ARID1A acts as a
tumor suppressor and coordinates with p53 protein to
regulate cellular growth [129]. However, inactivating
mutations of ARID1A alone do not appear to be sufficient
for tumor formation, but likely require additional genetic
alterations resulting in activation of the PI3K-Akt pathway
[130,131]. Activating mutations in PIK3CA are found in
33% of cases, PTEN loss in 12%, with alterations in
PI3K-Akt pathway occurring in 62% [131,132]. Preclinical
studies suggest that targeting the PI3K-Akt pathway
inhibits clear cell carcinoma tumor growth in a mouse
model and that loss of ARID1A further sensitizes
cells to PI3K- and Akt-inhibition [133,134]. Clinical
trials of agents targeting the PI3K-Akt pathway are
ongoing (NCT02142803, NCT01196429).
Endometrioid carcinoma
Similar to the dualistic pathway of pathogenesis of
serous carcinomas, molecular profiling of high-grade
endometrioid carcinomas are notable for mutations in
TP53 with the absence of other molecular alterations,
while low-grade endometrioid carcinomas were strongly
associated with microsatellite instability (20%), CTNNB1
mutations (~50%), and KRAS mutations (up to 35%)
[135-137]. High-grade endometrioid carcinomas were
found to have a gene expression profile similar to HGSC
[93]. Low-grade endometrioid carcinomas, however, are
similar to clear cell adenocarcinomas in their association
with endometriosis, expression of ARID1A mutations, and
activation of the PI3K-Akt pathway. Ovarian endometrioid
carcinomas are characterized by frequent somatic ARID1A
inactivating mutations (30-55% of cases) [127,137,138].
Mutations typically are deletion or nonsense mutations
which result in loss of protein expression [139]. ARID1A
loss is associated with loss of PTEN and mutations in
PIK3CA resulting in increased activation of the PI3K-Akt
pathway [140]. It has been demonstrated in a genetically
engineered mouse model that co-deletion of ARID1A and
PTEN results in the formation of ovarian carcinoma
with morphological and molecular features resembling
human ovarian endometrioid carcinoma [130]. Activating
mutations of PIK3CA are found in 20% of endometrioid
carcinomas, while mutations in PTEN are present in
14-20%, and loss of heterozygosity of PTEN was present
in 42% [136,137,141,142]. Loss of ARID1A has also been
identified in endometrial hyperplasia with atypia, the
precursor lesion of endometrioid carcinoma, and appears
to be an early event in its pathogenesis [143]. However,
despite the similarities between clear cell carcinomas and
endometrioid carcinomas in ARID1A and PI3K-Akt path-
way aberrations, protein array analysis showed differential
expression between the two subtypes with endometrioid
carcinomas expressing higher levels of steroid hormonereceptors (ER and PR), and clear cell carcinomas express-
ing higher levels of Cyclin E, SMAD3, and e-cadherin
[140]. Similarly, BRAF mutations were identified in 24% of
endometrioid carcinomas, but were not identified in any
case of clear cell carcinoma [107].
Other mutations frequently found in low-grade
endometrioid carcinomas include mutations in CTNNB1
(the gene that encodes beta-catenin) and mutations in
mismatch repair genes. Mutations in CTNNB1 are found
in up to 50% of endometrioid ovarian tumors and are
associated with improved outcomes [135-137]. Mutations
typically result in over-expression of nuclear beta-catenin
and increased transcription of down-stream target genes,
such as the proto-oncogene MYC. These changes are
present in a majority of borderline endometrioid ovarian
tumors suggesting it is an early event in tumorigenesis
[144]. Patients with Lynch syndrome are also at risk for
developing EOC, most commonly the endometrioid
subtype. Microsatellite instability has been detected in
up to 20% of endometrioid tumors [136]. Similar to
other Lynch-associated tumors, these tumors often
exhibit abnormal mismatch repair protein expression
with complete loss of MLH1, MSH2, MSH6, and/or
PMS2 [145].
Conclusions
Our review of the molecular, genetic, and histopatho-
logic data supports the comprehensive inclusion of
epithelial ovarian, tubal, and peritoneal cancers, as well
as select CUP, as adenocarcinomas of Mullerian origin.
While the dualistic Type I and II model of epithelial
ovarian cancer suggests two main categories, it is
unclear if this model can be extended to adenocarcinomas
of Mullerian origin. However, it is clear that the different
histologic subtypes within these categories are distinct
with regard to clinical outcome, pathophysiologic, and
molecular features which may have therapeutic implica-
tions. In light of the aforementioned advancements in
genomics we propose a new nomenclature for this set of
diseases. The terminology may include adenocarcinoma of
Mullerian origin, followed by presumed primary site
(ovary, fallopian tube, peritoneum), histologic subtype, and
mutation status (if relevant). This type of nomenclature
would appropriately capture the similarities among
adenocarcinomas of Mullerian origin in both origin
and histology, but recognize the unique molecular
differences between them, all of which inform treatment
decisions and prognosis. An example of such a classifica-
tion could be “adenocarcinoma of Mullerian origin, fallo-
pian tube primary, high-grade serous histology, BRCA1
mutation." Currently, the standard treatment of adenocar-
cinomas of Mullerian origin includes cytoreductive sur-
gery and multi-agent platinum-based chemotherapy. The
advances made in understanding the underlying molecular
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well as development of targeted therapeutics, will enable
the implementation of genomic-driven treatment deci-
sions in the future, elucidation of novel targets that
can be used in preventive strategies, and better iden-
tification of precursor lesions that will yield improved
survival outcomes.
Competing interests
Dr. Secord reports grant support from Precision Therapeutics, Sanofi-Aventis,
Genentech, Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bristol-Myers
Squibb (BMS), Incyte, Boerhinger Ingelheim, Tesaro, Eisai-Morphotek,
Endocyte/Merck, Amgen, and Astra-Zeneca. She also discloses that she
has served as a consultant for Precision Therapeutics, Genentech, GSK,
and Boerhinger Ingelheim. All other authors report no competing interests.
Authors’ contributions
AAS, LPC, SG, YW, and IS all provided substantial contributions to conception
and drafting of this review. AAS and LPC were primarily responsible for
drafting sections regarding background, incidence, classification and origin;
YW and IS were primarily responsible for drafting the section regarding
pathological analysis; SG was primarily responsible for drafting the section
regarding molecular determinants. All authors read and approved the final
version of the manuscript.
Acknowledgements
We’d like to thank Rex Bentley, MD in the Duke Department of Pathology for
providing the additional pathologic images used in Figure 4.
Author details
1Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, Duke Cancer Institute, Duke University Medical Center, Durham,
NC 27710, USA. 2Division of Medical Oncology, Department of Internal
Medicine, Duke University Medical Center, Durham, NC 27710, USA.
3Department of Gynecology and Obstetrics, Johns Hopkins University School
of Medicine, Baltimore, MD 21205, USA.
Received: 15 December 2014 Accepted: 17 March 2015
References
1. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary
cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol.
1959;77(1):197–200.
2. Prat J. Staging classification for cancer of the ovary, fallopian tube, and
peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. doi:10.1016/
j.ijgo.2013.10.001.
3. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian,
fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014.
doi:10.1007/s00404-014-3364-8.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin.
2013;63(1):11–30. doi:10.3322/caac.21166.
5. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,
Bray, F., 2012 G. Cancer Incidence and Mortality Worldwide: IARC CancerBase
No. 11 [Internet]. In: Lyon FIAfRoC, editor. Internet. Lyon, France2012.
6. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian
tube carcinomas in the United States, 1995–2004. Cancer Epidemiol
Biomarkers Prev. 2009;18(1):132–9. doi:10.1158/1055-9965.epi-08-0771.
7. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma:
a review. Oncologist. 2006;11(8):902–12. doi:10.1634/theoncologist.11-8-902.
8. Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube
carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):155–61.
doi:10.1016/j.ejogrb.2013.03.023.
9. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet.
2012;379(9824):1428–35. doi:10.1016/s0140-6736(11)61178-1.
10. Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB,
Hornick JL, et al. Cancer of unknown primary sites: what radiologists
need to know and what oncologists want to know. AJR Am J Roentgenol.
2013;200(3):484–92. doi:10.2214/ajr.12.9363.11. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in
cancer of unknown primary: from autopsy to microarray. Eur J Cancer.
2007;43(14):2026–36. doi:10.1016/j.ejca.2007.06.023.
12. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma
(serous) of Mullerian type: a subgroup of women presenting with peritoneal
carcinomatosis. Int J Gynecol Cancer. 1994;4(1):43–51.
13. Koshiyama M, Matsumura N. Recent concepts of ovarian carcinogenesis:
type I and type II. 2014;2014:934261. doi:10.1155/2014/934261.
14. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian
cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43.
doi:10.1097/PAS.0b013e3181cf3d79.
15. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23
suppl 10:x111–x7. doi:10.1093/annonc/mds300.
16. Soslow RA. Histologic Subtypes of Ovarian Carcinoma: An Overview. Int J
Gynecol Pathol. 2008;27(2):161–74. doi:10.1097/PGP.0b013e31815ea812.
17. Erickson BK, Conner MG, Landen Jr CN. The role of the fallopian tube in the
origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14.
doi:10.1016/j.ajog.2013.04.019.
18. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers.
Nat Rev Cancer. 2004;4(10):814–9. doi:10.1038/nrc1457.
19. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ.
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol
Oncol. 2003;90(2):491.
20. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53
mutations in serous tubal intraepithelial carcinoma and concurrent pelvic
high-grade serous carcinoma–evidence supporting the clonal relationship
of the two lesions. J Pathol. 2012;226(3):421–6. doi:10.1002/path.3023.
21. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al.
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma:
Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9.
doi:10.1097/01.pas.0000213335.40358.47.
22. C Nay Fellay MF, Delaloye FF, Bauer J. Extraovarian Primary Peritoneal
Carcinoma. Management of Rare Adult Tumours. Paris: Springer Publishing
Company; 2010. p. 279–92.
23. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma:
unknown primary tumour, ovarian cancer counterpart or a distinct
entity? A systematic review. Crit Rev Oncol Hematol. 2010;75(1):27–42.
doi:10.1016/j.critrevonc.2009.10.003.
24. Roh SY, Hong SH, Ko YH, Kim TH, Lee MA, Shim BY, et al. Clinical
characteristics of primary peritoneal carcinoma. Cancer Res Treat.
2007;39(2):65–8. doi:10.4143/crt.2007.39.2.65.
25. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface
epithelium: biology, endocrinology, and pathology. Endocr Rev.
2001;22(2):255–88. doi:10.1210/edrv.22.2.0422.
26. Lauchlan SC. The secondary Mullerian system. Obstet Gynecol Surv.
1972;27(3):133–46.
27. Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent
concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8.
doi:10.1186/1756-8722-5-8.
28. Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, et al.
Risk of developing ovarian cancer among women with ovarian
endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer.
2007;17(1):37–43. doi:10.1111/j.1525-1438.2006.00754.x.
29. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a
hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol.
1997;176(3):572–9.
30. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al.
Ovarian cancer risk associated with varying causes of infertility. Fertil Steril.
2004;82(2):405–14. doi:10.1016/j.fertnstert.2004.02.109.
31. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and
the development of malignant tumours of the pelvis. A review of literature.
Best Pract Res Clin Obstet Gynaecol. 2004;18(2):349–71. doi:10.1016/
j.bpobgyn.2003.03.001.
32. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma.
Pathology. 2013;45(3):229–42. doi:10.1097/PAT.0b013e32835f2264.
33. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous
carcinoma: pathogenesis, clinicopathologic and molecular biologic features,
and diagnostic problems. Adv Anat Pathol. 2009;16(5):267–82.
doi:10.1097/PAP.0b013e3181b4fffa.
34. Alvarez AA, Moore WF, Robboy SJ, Bentley RC, Gumbs C, Futreal PA, et al.
K-ras mutations in Mullerian inclusion cysts associated with serous borderline
Cobb et al. Gynecologic Oncology Research and Practice  (2015) 2:1 Page 14 of 16tumors of the ovary. Gynecol Oncol. 2001;80(2):201–6. doi:10.1006/
gyno.2000.6066.
35. Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Sharma R, Russell P
et al. Genomic classification of serous ovarian cancer with adjacent borderline
differentiates RAS-pathway and TP53-mutant tumors and identifies NRAS as an
oncogenic driver. Clin Cancer Res. 2014. doi:10.1158/1078-0432.ccr-14-1292.
36. Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and
high-grade serous neoplasms. Histopathology. 2013;62(1):44–58.
doi:10.1111/his.12046.
37. Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, et al. Tubal
origin of 'ovarian' low-grade serous carcinoma. Mod Pathol.
2011;24(11):1488–99. doi:10.1038/modpathol.2011.106.
38. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH,
et al. Dysplastic changes in prophylactically removed Fallopian tubes of
women predisposed to developing ovarian cancer. J Pathol.
2001;195(4):451–6. doi:10.1002/path.1000.
39. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A
candidate precursor to serous carcinoma that originates in the distal
fallopian tube. J Pathol. 2007;211(1):26–35. doi:10.1002/path.2091.
40. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic
(nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol.
2010;34(10):1407–16. doi:10.1097/PAS.0b013e3181ef7b16.
41. Dehari R, Kurman RJ, Logani S, Shih IM. The development of high-grade
serous carcinoma from atypical proliferative (borderline) serous tumors and
low-grade micropapillary serous carcinoma: a morphologic and molecular
genetic analysis. Am J Surg Pathol. 2007;31(7):1007–12. doi:10.1097/
PAS.0b013e31802cbbe9.
42. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T,
et al. Hematogenous metastasis of ovarian cancer: rethinking mode of
spread. Cancer Cell. 2014;26(1):77–91. doi:10.1016/j.ccr.2014.05.002.
43. Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, et al.
Extraovarian peritoneal serous papillary carcinoma: a case–control
retrospective comparison to papillary adenocarcinoma of the ovary.
Gynecol Oncol. 1993;50(3):347–51. doi:10.1006/gyno.1993.1223.
44. Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL.
Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin
and cyclophosphamide with comparison to a cohort with papillary serous
ovarian carcinoma—a Gynecologic Oncology Group Study. Gynecol Oncol.
2003;89(1):148–54. doi:http://dx.doi.org/10.1016/S0090-8258(03)00068-4.
45. Khalifeh I, Munkarah AR, Lonardo F, Malone JM, Morris R, Lawrence WD,
et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with
primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Int J Gynecol Pathol. 2004;23(2):162–9.
46. Killackey MA, Davis AR. Papillary Serous Carcinoma of the Peritoneal Surface:
Matched-Case Comparison with Papillary Serous Ovarian Carcinoma. Gynecol
Oncol. 1993;51(2):171–4. doi:http://dx.doi.org/10.1006/gyno.1993.1267.
47. Barda G, Menczer J, Chetrit A, Lubin F, Beck D, Piura B, et al. Comparison
between primary peritoneal and epithelial ovarian carcinoma: a population-based
study. Am J Obstet Gynecol. 2004;190(4):1039–45. doi:10.1016/j.ajog.2003.09.073.
48. Ayhan A, Taskiran C, Yigit-Celik N, Bozdag G, Gultekin M, Usubutun A, et al.
Long-term survival after paclitaxel plus platinum-based combination
chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it
different from that for ovarian serous papillary cancer? Int J Gynecol
Cancer. 2006;16(2):484–9. doi:10.1111/j.1525-1438.2006.00590.x.
49. Dubernard G, Morice P, Rey A, Camatte S, Fourchotte V, Thoury A, et al.
Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J
Surg Oncol. 2004;30(9):976–81. doi:http://dx.doi.org/10.1016/j.ejso.2004.08.005.
50. Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MHN,
Atkinson K, et al. Extraovarian peritoneal serous papillary carcinoma. A
clinicopathologic study of 31 cases. Cancer. 1989;64(1):110–5. doi:10.1002/
1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5.
51. Schorge JO, Miller YB, Qi L-J, Muto MG, Welch WR, Berkowitz RS, et al.
Genetic Alterations of the WT1 Gene in Papillary Serous Carcinoma of the
Peritoneum. Gynecol Oncol. 2000;76(3):369–72. doi:http://dx.doi.org/
10.1006/gyno.1999.5711.
52. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary
peritoneal serous papillary carcinoma: a new epidemiologic trend? A
matched-case comparison with ovarian serous papillary cancer. Int J Gynecol
Cancer. 2001;11(5):403–8.
53. Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML,
Sabbatini PJ, et al. Platinum resistance and impaired survival in patientswith advanced primary peritoneal carcinoma: matched-case comparison
with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol.
2008;198(2):213.e1–e7. doi:http://dx.doi.org/10.1016/j.ajog.2007.07.003.
54. Schnack TH, Sorensen RD, Nedergaard L, Hogdall C. Demographic clinical
and prognostic characteristics of primary ovarian, peritoneal and tubal
adenocarcinomas of serous histology–a prospective comparative study.
Gynecol Oncol. 2014;135(2):278–84. doi:10.1016/j.ygyno.2014.08.020.
55. Dunn MS, Manahan KJ, Geisler JP. Primary carcinoma of the fallopian tube
and epithelial ovarian carcinoma: A case–control analysis. J Reprod Med.
2008;53(9):691–4.
56. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, et al.
Serous fallopian tube carcinoma: A retrospective, multi-institutional case–control
comparison to serous adenocarcinoma of the ovary. Gynecol Oncol.
2007;107(3):398–403. doi:http://dx.doi.org/10.1016/j.ygyno.2007.09.027.
57. Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, et al. Survival
differences in women with serous tubal, ovarian, peritoneal, and uterine
carcinomas. Am J Obstet Gynecol. 2015;212(2):188.e1–6. doi:10.1016/
j.ajog.2014.08.016.
58. Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, et al.
Improved survival for fallopian tube cancer. Cancer. 2008;113(12):3298–306.
doi:10.1002/cncr.23957.
59. Tanyi JL, Scholler N. Oncology biomarkers for gynecologic malignancies.
Front Biosci. 2012;4:1097–110.
60. Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J. The significance
of the pattern of serum CA125 level ascent to above the normal range in
epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol
Oncol. 2013;129(1):165–8. doi:http://dx.doi.org/10.1016/j.ygyno.2012.12.024.
61. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4
offers superior specificity in the differentiation of benign and malignant
adnexal masses in premenopausal women. Am J Obstet Gynecol.
2011;205(4):358.e1–6. doi:10.1016/j.ajog.2011.05.017.
62. Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, et al.
Immunophenotyping of serous carcinoma of the female genital tract. Mod
Pathol. 2008;21(9):1147–55.
63. Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited
panel of immunomarkers can reliably distinguish between clear cell and
high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33(1):14–21.
doi:10.1097/PAS.0b013e3181788546.
64. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8
reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Am J Surg Pathol. 2010;34(5):627–35. doi:10.1097/PAS.0b013e3181da7687.
65. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia.
Am J Clin Pathol. 2002;117(6):944–51. doi:10.1309/2t1y-7bb7-dape-pq6l.
66. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2
immunohistochemistry in the identification of metastatic Mullerian carcinoma
in effusions. Diagn Cytopathol. 2011;39(9):651–6. doi:10.1002/dc.21442.
67. Hou T, Liang D, He J, Chen X, Zhang Y. Primary peritoneal serous
carcinoma: a clinicopathological and immunohistochemical study of six
cases. Int J Clin Exp Pathol. 2012;5(8):762–9.
68. Liu Q, Lin JX, Shi QL, Wu B, Ma HH, Sun GQ. Primary peritoneal serous
papillary carcinoma: a clinical and pathological study. Pathol Oncol Res.
2011;17(3):713–9. doi:10.1007/s12253-011-9375-x.
69. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and
epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in
females from serous papillary carcinoma of the ovary and peritoneum.
Histopathology. 2002;40(3):237–44.
70. Schmeler KM, Sun CC, Malpica A, Deavers MT, Bodurka DC, Gershenson DM.
Low-grade serous primary peritoneal carcinoma. Gynecol Oncol.
2011;121(3):482–6. doi:10.1016/j.ygyno.2011.02.017.
71. Seidman JD. Mucinous lesions of the fallopian tube. A report of seven cases.
Am J Surg Pathol. 1994;18(12):1205–12.
72. Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8
expression in non-neoplastic tissues, primary tumors, and metastatic tumors:
a comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751–64.
doi:10.1038/modpathol.2011.3.
73. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation
in human benign, low malignant potential, and invasive epithelial ovarian
tumors. Cancer. 2003;97(2):389–404. doi:10.1002/cncr.11064.
74. Kamal CK, Simionescu CE, Margaritescu C, Stepan A. P53 and Ki67
immunoexpression in mucinous malignant ovarian tumors. Rom J Morphol
Embryol. 2012;53(3 Suppl):799–803.
Cobb et al. Gynecologic Oncology Research and Practice  (2015) 2:1 Page 15 of 1675. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous,
endometrioid, clear cell, and mucinous carcinomas of the peritoneum,
fallopian tube, ovary, and endometrium. Int J Gynecol Pathol.
2004;23(2):110–8.
76. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the
fallopian tube: a clinicopathological study of 105 cases with observations on
staging and prognostic factors. Gynecol Oncol. 1999;72(3):367–79.
doi:10.1006/gyno.1998.5267.
77. de la Torre FJ, Rojo F, Garcia A. Clear cells carcinoma of fallopian tubes
associated with tubal endometriosis. Case report and review. Arch Gynecol
Obstet. 2002;266(3):172–4.
78. Ryuko K, Iwanari O, Abu-Musa A, Fujiwaki R, Kitao M. Primary clear cell
adenocarcinoma of the fallopian tube with brain metastasis: a case report.
Asia-Oceania J Obstet Gynaecol. 1994;20(2):135–40.
79. Wuntakal R, Lawrence A. Are oestrogens and genetic predisposition
etiologic factors in the development of clear cell carcinoma of the
peritoneum? Med Hypotheses. 2013;80(2):167–71. doi:10.1016/
j.mehy.2012.11.021.
80. Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade
serous and undifferentiated carcinoma compared with other morphologic
types of ovarian carcinoma. Int J Gynecol Pathol. 2009;28(2):179–86.
doi:10.1097/PGP.0b013e318182c2d2.
81. DeLair D, Oliva E, Kobel M, Macias A, Gilks CB, Soslow RA. Morphologic
spectrum of immunohistochemically characterized clear cell carcinoma of
the ovary: a study of 155 cases. Am J Surg Pathol. 2011;35(1):36–44.
doi:10.1097/PAS.0b013e3181ff400e.
82. Cameron RI, Ashe P, O'Rourke DM, Foster H, McCluggage WG. A panel of
immunohistochemical stains assists in the distinction between ovarian and
renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22(3):272–6.
doi:10.1097/01.pgp.0000071044.12278.43.
83. Irving JA, Catasus L, Gallardo A, Bussaglia E, Romero M, Matias-Guiu X, et al.
Synchronous endometrioid carcinomas of the uterine corpus and ovary:
alterations in the beta-catenin (CTNNB1) pathway are associated with
independent primary tumors and favorable prognosis. Hum Pathol.
2005;36(6):605–19. doi:10.1016/j.humpath.2005.03.005.
84. Fujiwaki R, Takahashi K, Ryuko K, Watanabe Y, Nishiki Y, Kitao M. Primary
endometrioid carcinoma of the fallopian tube. Acta Obstet Gynecol Scand.
1996;75(5):508–10.
85. Navani SS, Alvarado-Cabrero I, Young RH, Scully RE. Endometrioid carcinoma
of the fallopian tube: a clinicopathologic analysis of 26 cases. Gynecol
Oncol. 1996;63(3):371–8. doi:10.1006/gyno.1996.0338.
86. Rabczynski J, Ziolkowski P. Primary endometrioid carcinoma of fallopian
tube. Clinicomorphologic study. Pathol Oncol Res. 1999;5(1):61–6.
87. Alvarado-Cabrero I, Navani SS, Young RH, Scully RE. Tumors of the
fimbriated end of the fallopian tube: a clinicopathologic analysis of 20
cases, including nine carcinomas. Int J Gynecol Pathol. 1997;16(3):189–96.
88. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian
and extraovarian endometriosis-associated cancer. Obstet Gynecol.
2002;100(4):788–95.
89. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis.
Obstet Gynecol. 1990;75(6):1023–8.
90. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy
in endometriosis: frequency and comparison of ovarian and extraovarian
types. Int J Gynecol Pathol. 2001;20(2):133–9.
91. Caduff RF, Svoboda-Newman SM, Bartos RE, Ferguson AW, Frank TS.
Comparative analysis of histologic homologues of endometrial and ovarian
carcinoma. Am J Surg Pathol. 1998;22(3):319–26.
92. Integrated genomic analyses of ovarian carcinoma. Nature.
2011;474(7353):609–15. doi:10.1038/nature10166.
93. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel
molecular subtypes of serous and endometrioid ovarian cancer linked
to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208.
doi:10.1158/1078-0432.ccr-08-0196.
94. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot Chad V, et al. Integrated Analyses
Identify a Master MicroRNA Regulatory Network for the Mesenchymal
Subtype in Serous Ovarian Cancer. Cancer Cell. 2013;23(2):186–99.
doi:http://dx.doi.org/10.1016/j.ccr.2012.12.020.
95. Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al.
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as
a predictor of outcome following bevacizumab. J Clin Oncol.
2014;32(5s):(suppl; abstr 5502).96. Boris JN, Winterhoff SK, Oberg AL, Wang C, Riska SM, Konecny GE, et al.
Bevacizumab and improvement of progression-free survival (PFS) for
patients with the mesenchymal molecular subtype of ovarian cancer. J Clin
Oncol. 2014;32(5s):(suppl; abstr 5509).
97. Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Kujawa K, Grzybowska E,
et al. Gene expression analysis in ovarian cancer - faults and hints from DNA
microarray study. Front Oncol. 2014;4:6. doi:10.3389/fonc.2014.00006.
98. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of
ovarian and uterine carcinosarcomas–a CGH and FISH study. Virchows Arch.
2008;452(3):259–68. doi:10.1007/s00428-007-0557-6.
99. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D,
Cowin P et al. Copy number analysis identifies novel interactions between
genomic loci in ovarian cancer. PloS One. 2010;5(9). doi:10.1371/
journal.pone.0011408.
100. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R,
et al. Driver mutations in TP53 are ubiquitous in high grade serous
carcinoma of the ovary. J Pathol. 2010;221(1):49–56. doi:10.1002/path.2696.
101. Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, et al. STICS,
SCOUTs and p53 signatures; a new language for pelvic serous
carcinogenesis. Front Biosci. 2011;3:625–34.
102. Espinosa I, Catasus L, Canet B, D'Angelo E, Munoz J, Prat J. Gene expression
analysis identifies two groups of ovarian high-grade serous carcinomas with
different prognosis. Mod Pathol. 2011;24(6):846–54. doi:10.1038/
modpathol.2011.12.
103. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, et al. Unique
gene expression profile based on pathologic response in epithelial ovarian
cancer. J Clin Oncol. 2005;23(31):7911–8. doi:10.1200/JCO.2005.02.9363.
104. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. Patterns
of gene expression that characterize long-term survival in advanced
stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686–96.
doi:10.1158/1078-0432.CCR-04-2398.
105. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An
immunohistochemical comparison between low-grade and high-grade ovarian
serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu,
and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29(8):1034–41.
106. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of
p53 mutations separate ovarian serous borderline tumors and low- and
high-grade carcinomas and provide support for a new model of ovarian
carcinogenesis: a mutational analysis with immunohistochemical correlation.
Am J Surg Pathol. 2005;29(2):218–24.
107. Singer G, Oldt 3rd R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al.
Mutations in BRAF and KRAS characterize the development of low-grade
ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.
108. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B,
et al. Low-grade serous carcinomas of the ovary contain very few point
mutations. J Pathol. 2012;226(3):413–20. doi:10.1002/path.3967.
109. Prat J. Ovarian carcinomas: five distinct diseases with different origins,
genetic alterations, and clinicopathological features. Virchows Arch.
2012;460(3):237–49. doi:10.1007/s00428-012-1203-5.
110. Gershenson DM. The life and times of low-grade serous carcinoma of the
ovary. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/
EdBook_AM.2013.33.e195.
111. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al.
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecol Oncol. 2009;114(1):48–52. doi:10.1016/j.ygyno.2009.03.001.
112. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA,
et al. Selumetinib in women with recurrent low-grade serous carcinoma of
the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet
Oncol. 2013;14(2):134–40. doi:10.1016/s1470-2045(12)70572-7.
113. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al.
Molecular characterization of mucinous ovarian tumours supports a
stratified treatment approach with HER2 targeting in 19% of carcinomas.
J Pathol. 2013;229(1):111–20. doi:10.1002/path.4088.
114. Bos JL. ras oncogenes in human cancer: a review. Cancer Res.
1989;49(17):4682–9.
115. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous
ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cancer. 1997;79(8):1581–6.
116. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, et al.
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gynecol Oncol. 2003;90(2):378–81.
Cobb et al. Gynecologic Oncology Research and Practice  (2015) 2:1 Page 16 of 16117. Nodin B, Zendehrokh N, Sundstrom M, Jirstrom K. Clinicopathological
correlates and prognostic significance of KRAS mutation status in a pooled
prospective cohort of epithelial ovarian cancer. Diagnostic Pathol.
2013;8:106. doi:10.1186/1746-1596-8-106.
118. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on
diagnosis and management. Curr Oncol Rep. 2014;16(6):389.
doi:10.1007/s11912-014-0389-x.
119. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, et al. Dual-colour
HER2/chromosome 17 chromogenic in situ hybridisation enables accurate
assessment of HER2 genomic status in ovarian tumours. J Clin Pathol.
2011;64(12):1097–101. doi:10.1136/jclinpath-2011-200082.
120. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, et al. HER2
amplification and clinicopathological characteristics in a large Asian cohort
of rare mucinous ovarian cancer. PLoS One. 2013;8(4), e61565.
doi:10.1371/journal.pone.0061565.
121. Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, et al.
Histotype-specific copy-number alterations in ovarian cancer.
BMC Med Genom. 2012;5:47. doi:10.1186/1755-8794-5-47.
122. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al.
HER2 overexpression and amplification is present in a subset of ovarian
mucinous carcinomas and can be targeted with trastuzumab therapy.
BMC Cancer. 2009;9:433. doi:10.1186/1471-2407-9-433.
123. Jain A, Ryan PD, Seiden MV. Metastatic mucinous ovarian cancer and
treatment decisions based on histology and molecular markers rather than
the primary location. J Natl Compr Canc Netw. 2012;10(9):1076–80.
124. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ,
et al. Gene expression profiles of serous, endometrioid, and clear cell
subtypes of ovarian and endometrial cancer. Clin Cancer Res.
2005;11(18):6422–30. doi:10.1158/1078-0432.ccr-05-0508.
125. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al.
Gene expression in ovarian cancer reflects both morphology and biological
behavior, distinguishing clear cell from other poor-prognosis ovarian
carcinomas. Cancer Res. 2002;62(16):4722–9.
126. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, et al.
Identification of novel therapeutic targets in microdissected clear cell
ovarian cancers. PLoS One. 2011;6(7), e21121. doi:10.1371/
journal.pone.0021121.
127. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A
Mutations in Endometriosis-Associated Ovarian Carcinomas. N Engl J Med.
2010;363(16):1532–43. doi:doi:10.1056/NEJMoa1008433.
128. Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, et al. Loss of ARID1A
expression is an early molecular event in tumor progression from ovarian
endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol
Cancer. 2012;22(8):1310–5. doi:10.1097/IGC.0b013e31826b5dcc.
129. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of
SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in
gynecologic cancers. Cancer Res. 2011;71(21):6718–27. doi:10.1158/0008-
5472.can-11-1562.
130. Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL et al. Roles of
deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
J Nat Cancer Inst. 2014;106(7). doi:10.1093/jnci/dju146.
131. Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT. Loss of ARID1A
expression and its relationship with PI3K-Akt pathway alterations and
ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol.
2014;27(7):983–90. doi:10.1038/modpathol.2013.216.
132. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent
activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol.
2009;174(5):1597–601. doi:10.2353/ajpath.2009.081000.
133. Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, et al. The
PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear
cell carcinoma. Oncol Rep. 2014;32(2):553–8. doi:10.3892/or.2014.3268.
134. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of
ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Oncotarget. 2014;5(14):5295–303.
135. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, Banon-Rodriguez I,
Hernandez-Cortes G, Hardisson D, et al. Expression of cadherins and
catenins correlates with distinct histologic types of ovarian carcinomas.
Hum Pathol. 2006;37(8):1042–9. doi:10.1016/j.humpath.2006.03.003.
136. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, Sarrio D, Moreno-Bueno G,
Franceschetti I, et al. Pathogenetic pathways in ovarian endometrioidadenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol.
2009;33(8):1157–63. doi:10.1097/PAS.0b013e3181a902e1.
137. Gadducci A, Lanfredini N, Tana R. Novel insights on the malignant
transformation of endometriosis into ovarian carcinoma. Gynecol
Endocrinol. 2014;30(9):612–7. doi:10.3109/09513590.2014.926325.
138. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and
loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Am J Surg Pathol. 2011;35(5):625–32. doi:10.1097/PAS.0b013e318212782a.
139. Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor
suppression. Canc Biol Ther. 2014;15(6):655–64. doi:10.4161/cbt.28411.
140. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, et al. A
functional proteogenomic analysis of endometrioid and clear cell carcinomas
using reverse phase protein array and mutation analysis: protein expression is
histotype-specific and loss of ARID1A/BAF250a is associated with AKT
phosphorylation. BMC Cancer. 2014;14:120. doi:10.1186/1471-2407-14-120.
141. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of
heterozygosity on 10q23.3 and mutation of the tumor suppressor gene
PTEN in benign endometrial cyst of the ovary: possible sequence
progression from benign endometrial cyst to endometrioid carcinoma and
clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052–6.
142. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML,
Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer.
Cancer Res. 2004;64(21):7678–81. doi:10.1158/0008-5472.can-04-2933.
143. Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, et al.
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade
endometrioid carcinomas. Mod Pathol. 2013;26(3):428–34. doi:10.1038/
modpathol.2012.174.
144. Oliva E, Sarrio D, Brachtel EF, Sanchez-Estevez C, Soslow RA, Moreno-Bueno G,
et al. High frequency of beta-catenin mutations in borderline endometrioid
tumours of the ovary. J Pathol. 2006;208(5):708–13. doi:10.1002/path.1923.
145. Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian
endometrioid adenocarcinoma: incidence and clinical significance of the
morphologic and immunohistochemical markers of mismatch repair protein
defects and tumor microsatellite instability. Am J Surg Pathol.
2012;36(2):163–72. doi:10.1097/PAS.0b013e31823bc434.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
